Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, liver, IPF, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-2-94547200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.60 million
Profitability
Miscellaneous
Employees64
Next Earnings DateN/A
OptionableNot Optionable
Pharmaxis (ASX:PXS) Frequently Asked Questions
What is Pharmaxis' stock symbol?
Pharmaxis trades on the ASX under the ticker symbol "PXS."
Has Pharmaxis been receiving favorable news coverage?
Press coverage about PXS stock has trended positive on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pharmaxis earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are some of Pharmaxis' key competitors?
Some companies that are related to Pharmaxis include Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Opthea (OPT), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Futura Medical (FUM), Vita Life Sciences (VLS), Cathay International (CTI), Patrys (PAB), Recce Pharmaceuticals (RCE), Avivagen (VIV), Antisense Therapeutics (ANP), NanoViricides (NNVC) and Sareum (SAR).
What other stocks do shareholders of Pharmaxis own?
Who are Pharmaxis' key executives?
Pharmaxis' management team includes the folowing people:
- Mr. Gary Jonathan Phillips, CEO & Director (Age 58)
- Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 63)
- Mr. Wolfgang G. Jarolimek B.Sc. Ph.D., Head of Drug Discovery (Age 55)
- Dr. Brett Charlton MBBS Ph.D., Medical Director (Age 63)
- Ms. Kristen Morgan BSc, PGDipBusAdmin, MMedSc, Officer of Alliance Management & Medical and Regulatory Affairs (Age 47)
What is Pharmaxis' stock price today?
One share of PXS stock can currently be purchased for approximately A$0.28.
How big of a company is Pharmaxis?
Pharmaxis has a market capitalization of $110.41 million and generates $6.60 million in revenue each year. Pharmaxis employs 64 workers across the globe.
What is Pharmaxis' official website?
How can I contact Pharmaxis?
Pharmaxis' mailing address is 20 Rodborough Rd, FRENCHS FOREST, NSW 2086, Australia. The company can be reached via phone at +61-2-94547200.
MarketBeat Community Rating for Pharmaxis (ASX PXS)
MarketBeat's community ratings are surveys of what our community members think about Pharmaxis and other stocks. Vote "Outperform" if you believe PXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
